Conferences - Results from #60

ASTRO 2024: Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses September 30, 2024

ASTRO 2024: Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer September 30, 2024

ASTRO 2024: A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High-risk Prostate Cancer: Efficacy Results at Median 6 Years September 30, 2024

ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer September 30, 2024

ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer September 30, 2024

ASTRO 2024: Strategies and Evidence for SABR in RCC September 30, 2024

ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy September 29, 2024

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT) September 29, 2024

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial September 29, 2024

ASTRO 2024: Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial September 29, 2024

ASTRO 2024: The Space-Time Continuum in Metastatic Castration-Sensitive Prostate Cancer: The Final Frontier? September 29, 2024

ASTRO 2024: Bladder Preservation - A Modern Choice for Patients September 29, 2024

ASTRO 2024: Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP) September 29, 2024

ASTRO 2024: Precision in Practice: Optimizing Prostate Radiation with MRI-Defined Microboost September 29, 2024

ASTRO 2024: A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Prostatectomy September 29, 2024

ASTRO 2024: SABR for Primary RCC – Is It Ready for Primetime? September 29, 2024

ASTRO 2024: Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study September 29, 2024

ASTRO 2024: Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial September 29, 2024

ASTRO 2024: Impact of Prior Local Therapy on Treatment Response and Survival of Men with Metastatic Castrate Resistant Prostate Cancer: A Pooled Analysis of COU-AA-302 and ACIS Trials September 29, 2024

IBCN 2024: Mechanisms of Resistance to Antibody Drug Conjugates September 21, 2024

Page 4 of 589